Enhanced	Enhance	VBN	B-NP	O		0	8
virulence	virulence	NN	I-NP	O		9	18
of	of	IN	B-PP	O		19	21
Chlamydia muridarum	Chlamydia_muridarum	NN	B-NP	O		22	41
respiratory	respiratory	JJ	I-NP	O		42	53
infections	infection	NNS	I-NP	O		54	64
in	in	IN	B-PP	O		65	67
the	the	DT	B-NP	O		68	71
absence	absence	NN	I-NP	O		72	79
of	of	IN	B-PP	O		80	82
TLR2	TLR2	NN	B-NP	B-protein		83	87
activation	activation	NN	I-NP	O		88	98
.	.	.	O	O		98	99

Chlamydia trachomatis	Chlamydia_trachomatis	NN	B-NP	O		100	121
is	be	VBZ	B-VP	O		122	124
a	a	DT	B-NP	O		125	126
common	common	JJ	I-NP	O		127	133
sexually	sexually	RB	I-NP	O		134	142
transmitted	transmit	VBN	I-NP	O		143	154
pathogen	pathogen	NN	I-NP	O		155	163
and	and	CC	O	O		164	167
is	be	VBZ	B-VP	O		168	170
associated	associate	VBN	I-VP	O		171	181
with	with	IN	B-PP	O		182	186
infant	infant	NN	B-NP	O		187	193
pneumonia	pneumonia	NN	I-NP	O		194	203
.	.	.	O	O		203	204

Data	Datum	NNS	B-NP	O		205	209
from	from	IN	B-PP	O		210	214
the	the	DT	B-NP	O		215	218
female	female	JJ	I-NP	O		219	225
mouse	mouse	NN	I-NP	O		226	231
model	model	NN	I-NP	O		232	237
of	of	IN	B-PP	O		238	240
genital	genital	JJ	B-NP	O		241	248
tract	tract	NN	I-NP	O		249	254
chlamydia	chlamydia	NN	I-NP	O		255	264
infection	infection	NN	I-NP	O		265	274
suggests	suggest	VBZ	B-VP	O		275	283
a	a	DT	B-NP	O		284	285
requirement	requirement	NN	I-NP	O		286	297
for	for	IN	B-PP	O		298	301
TLR2	TLR2	NN	B-NP	B-protein		302	306
-	-	HYPH	B-NP	O		306	307
dependent	dependent	JJ	I-NP	O		307	316
signaling	signaling	NN	I-NP	O		317	326
in	in	IN	B-PP	O		327	329
the	the	DT	B-NP	O		330	333
induction	induction	NN	I-NP	O		334	343
of	of	IN	B-PP	O		344	346
inflammation	inflammation	NN	B-NP	O		347	359
and	and	CC	I-NP	O		360	363
oviduct	oviduct	NN	I-NP	O		364	371
pathology	pathology	NN	I-NP	O		372	381
.	.	.	O	O		381	382

We	We	PRP	B-NP	O		383	385
hypothesized	hypothesize	VBD	B-VP	O		386	398
that	that	IN	B-SBAR	O		399	403
the	the	DT	B-NP	O		404	407
role	role	NN	I-NP	O		408	412
of	of	IN	B-PP	O		413	415
TLR2	TLR2	NN	B-NP	B-protein		416	420
in	in	IN	B-PP	O		421	423
moderating	moderate	VBG	B-VP	O		424	434
mucosal	mucosal	JJ	B-NP	O		435	442
inflammation	inflammation	NN	I-NP	O		443	455
is	be	VBZ	B-VP	O		456	458
site	site	NN	B-NP	O		459	463
specific	specific	JJ	I-NP	O		464	472
.	.	.	O	O		472	473

In	In	IN	B-SBAR	O		474	476
order	order	NN	O	O		477	482
to	to	TO	B-VP	O		483	485
investigate	investigate	VB	I-VP	O		486	497
this	this	DT	B-NP	O		498	502
,	,	,	O	O		502	503
we	we	PRP	B-NP	O		504	506
infected	infect	VBD	B-VP	O		507	515
mice	mouse	NNS	B-NP	O		516	520
via	via	IN	B-PP	O		521	524
the	the	DT	B-NP	O		525	528
intranasal	intranasal	JJ	I-NP	O		529	539
route	route	NN	I-NP	O		540	545
with	with	IN	B-PP	O		546	550
C. muridarum	C._muridarum	NN	B-NP	O		551	563
and	and	CC	O	O		564	567
observed	observe	VBD	B-VP	O		568	576
that	that	IN	B-SBAR	O		577	581
in	in	IN	B-PP	O		582	584
the	the	DT	B-NP	O		585	588
absence	absence	NN	I-NP	O		589	596
of	of	IN	B-PP	O		597	599
TLR2	TLR2	NN	B-NP	B-protein		600	604
activation	activation	NN	I-NP	O		605	615
,	,	,	O	O		615	616
mice	mouse	NNS	B-NP	O		617	621
had	have	VBD	B-VP	O		622	625
more	more	RBR	B-NP	O		626	630
severe	severe	JJ	I-NP	O		631	637
disease	disease	NN	I-NP	O		638	645
,	,	,	O	O		645	646
higher	high	JJR	B-NP	O		647	653
lung	lung	NN	I-NP	B-protein		654	658
cytokine	cytokine	NN	I-NP	I-protein		659	667
levels	level	NNS	I-NP	O		668	674
,	,	,	O	O		674	675
and	and	CC	O	O		676	679
an	an	DT	B-NP	O		680	682
exaggerated	exaggerated	JJ	I-NP	O		683	694
influx	influx	NN	I-NP	O		695	701
of	of	IN	B-PP	O		702	704
neutrophils	neutrophil	NNS	B-NP	B-cell_type		705	716
and	and	CC	I-NP	O		717	720
T-cells	T-cell	NNS	I-NP	B-cell_type		721	728
into	into	IN	B-PP	O		729	733
the	the	DT	B-NP	O		734	737
lungs	lung	NNS	I-NP	O		738	743
.	.	.	O	O		743	744

This	This	DT	B-NP	O		745	749
could	could	MD	B-VP	O		750	755
not	not	RB	I-VP	O		756	759
be	be	VB	I-VP	O		760	762
explained	explain	VBN	I-VP	O		763	772
by	by	IN	B-PP	O		773	775
impaired	impaired	JJ	B-NP	O		776	784
bacterial	bacterial	JJ	I-NP	O		785	794
clearance	clearance	NN	I-NP	O		795	804
as	as	IN	B-PP	O		805	807
TLR2	TLR2	NN	B-NP	B-protein		808	812
-	-	HYPH	B-NP	O		812	813
deficient	deficient	JJ	I-NP	O		813	822
mice	mouse	NNS	I-NP	O		823	827
cleared	clear	VBD	B-VP	O		828	835
the	the	DT	B-NP	O		836	839
infection	infection	NN	I-NP	O		840	849
similar	similar	JJ	B-ADJP	O		850	857
to	to	TO	B-PP	O		858	860
controls	control	NNS	B-NP	O		861	869
.	.	.	O	O		869	870

These	These	DT	B-NP	O		871	876
data	datum	NNS	I-NP	O		877	881
suggest	suggest	VBP	B-VP	O		882	889
that	that	IN	B-SBAR	O		890	894
TLR2	TLR2	NN	B-NP	B-protein		895	899
has	have	VBZ	B-VP	O		900	903
an	an	DT	B-NP	O		904	906
anti	anti	AFX	I-NP	O		907	911
-	-	HYPH	I-NP	O		911	912
inflammatory	inflammatory	JJ	I-NP	O		912	924
function	function	NN	I-NP	O		925	933
in	in	IN	B-PP	O		934	936
the	the	DT	B-NP	O		937	940
lung	lung	NN	I-NP	O		941	945
during	during	IN	B-PP	O		946	952
Chlamydia	Chlamydia	NN	B-NP	O		953	962
infection	infection	NN	I-NP	O		963	972
,	,	,	O	O		972	973
and	and	CC	O	O		974	977
that	that	IN	B-SBAR	O		978	982
the	the	DT	B-NP	O		983	986
role	role	NN	I-NP	O		987	991
of	of	IN	B-PP	O		992	994
TLR2	TLR2	NN	B-NP	B-protein		995	999
in	in	IN	B-PP	O		1000	1002
mucosal	mucosal	JJ	B-NP	O		1003	1010
inflammation	inflammation	NN	I-NP	O		1011	1023
varies	vary	VBZ	B-VP	O		1024	1030
at	at	IN	B-PP	O		1031	1033
different	different	JJ	B-NP	O		1034	1043
mucosal	mucosal	JJ	I-NP	O		1044	1051
surfaces	surface	NNS	I-NP	O		1052	1060
.	.	.	O	O		1060	1061

